Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
PaperCitations, authors & open-access status
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 728 citations, 2019 year and closed oa status.
728
Citations
2019
Year
closed
OA Status